Welcome to our dedicated page for Alpha Tau Medical Ltd. SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Tau Medical Ltd. filings document the company's foreign-issuer current reports for Alpha DaRT clinical and regulatory updates. Recent Form 6-K reports furnish press releases and presentations covering studies in recurrent glioblastoma, recurrent cutaneous squamous cell carcinoma, pancreatic cancer, and head and neck cancer.
The filings describe trial enrollment, interim clinical data, safety observations, FDA device-related matters, conference presentations and company presentations furnished as exhibits. They also identify the company's Form 20-F reporting status and the treatment of furnished information under the Securities Exchange Act.
Alpha Tau Medical Ltd. director Alon Ruth filed an initial ownership report detailing his equity position in the company. He directly holds 29,367 ordinary shares, 4,680 restricted share units that vest in full upon the earlier of one year from March 9, 2026 or the next annual shareholder meeting, and multiple option grants over ordinary shares with exercise prices between $2.98 and $10.92. According to the footnotes, certain options are already fully vested, while others vest on the same future schedule as the restricted share units, all subject to his continued service.
Alpha Tau Medical Ltd. director Netser Maya filed an initial ownership report detailing current equity interests in the company. The filing shows direct ownership of 3,086 ordinary shares.
Maya also holds restricted share units representing 4,321 ordinary shares that vest in equal monthly installments over three years commencing on December 17, 2024, subject to continued service. An additional 4,680 restricted share units will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, also conditioned on continued service.
The report lists stock options to acquire 24,048 ordinary shares at an exercise price of $4.05 per share, vesting in equal monthly installments over three years commencing December 17, 2024, and expiring on January 22, 2035. Further options cover 15,527 ordinary shares at an exercise price of $6.41 per share, vesting in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, with an expiration date of March 9, 2036.
Alpha Tau Medical Ltd. executive Raphi Levy, the Chief Financial Officer, reports his current equity holdings in the company. He directly holds 180,180 ordinary shares, multiple option grants over ordinary shares with exercise prices ranging from 2.60 to 11.50 and expirations between 2029 and 2036, and several tranches of restricted share units.
The footnotes explain that certain restricted share unit grants vest in equal quarterly installments over three-year periods commencing January 1, 2024, January 1, 2025 and January 1, 2026, subject to his continued service. Some option grants are already fully vested, while others vest quarterly over similar three-year schedules tied to continued employment.
Alpha Tau Medical reported a larger net loss for 2025 while advancing its Alpha DaRT cancer therapy and strengthening its balance sheet. The company posted a 2025 net loss of $42.6 million, or $0.53 per share, compared with a $31.8 million loss, or $0.45 per share, in 2024, driven mainly by higher research and development and general and administrative costs.
R&D expenses rose to $32.1 million from $27.0 million, and G&A increased to $8.4 million from $6.7 million, while marketing expenses declined slightly. Despite the wider loss, cash, cash equivalents, short-term deposits and restricted deposits increased to $76.9 million as of December 31, 2025, up from $62.9 million a year earlier, supporting ongoing trials and commercial preparations. Recent milestones include Japanese marketing approval for Alpha DaRT, a fifth parallel U.S. trial approval, first brain cancer treatment using Alpha DaRT, and progress across pancreatic and glioblastoma studies.
Alpha Tau Medical Ltd. files its annual Form 20‑F as a clinical‑stage oncology company developing its Alpha DaRT local alpha‑radiation technology for solid tumors. The company has no product revenue and reported net losses of $31,750 and $42,627 for the years ended December 31, 2024 and 2025, respectively, with an accumulated deficit of $190,136 as of December 31, 2025.
As of that date, Alpha Tau had 88,009,737 ordinary shares outstanding. In April 2025 it sold 14,110,121 ordinary shares to Oramed Ltd. at $2.612 per share, generating net proceeds of about $36.7 million, and believes existing cash should fund operations for at least the next two years. The filing emphasizes extensive risks around ongoing losses, future funding needs, stringent global device regulation, clinical trial uncertainty and potential product liability as it seeks marketing authorization for Alpha DaRT across multiple cancer indications.
DRTS submitted a Form 144 notice identifying a proposed sale of 10,000 ordinary shares through Oppenheimer & Co. Inc.
The filing also lists 87,500 restricted stock units dated 08/08/2021 and records a prior sale by Levy Raphi of 60,000 ordinary shares on 01/08/2026 for $404,674.46.
Alpha Tau Medical Ltd. reported that Japan’s Ministry of Health, Labour and Welfare has granted Shonin marketing approval for its Alpha DaRT® therapy to treat unresectable locally advanced or locally recurrent head and neck cancer. This is the first regulatory approval for the Alpha DaRT platform outside Israel.
As a condition of approval, the company will run a post-market surveillance study in Japan, enrolling 66 patients across five leading clinical centers to further evaluate safety and clinical performance. Alpha Tau and its partner HekaBio are preparing for launch and plan discussions with Japanese authorities about potential reimbursement and additional clinical studies in other tumor types.
An insider has filed a notice of proposed sale under Rule 144 to sell 87,010 ordinary shares through Oppenheimer & Co. Inc. on or about 02/02/2026, with the shares listed on Nasdaq. The aggregate market value of this planned sale is stated as 603,849.40, based on the figures in the notice.
The insider, identified as Gat Amnon, previously sold ordinary shares of the same issuer during the past three months. These earlier sales were 16,000 shares on 11/03/2025 for 62,404.91, 33,351 shares on 12/01/2025 for 148,918.59, and 90,559 shares on 01/02/2026 for 549,741.24. The shares to be sold were originally acquired on 02/21/2017 through an employee stock option plan, with cash payment upon exercise.
Alpha Tau Medical Ltd. provides a detailed update on its Alpha DaRT cancer therapy program, highlighting an expectedly active 2026 with multiple clinical and regulatory milestones. The company now has five concurrently approved trials in the U.S., alongside studies in Europe, Japan and Israel.
Management targets completion of patient recruitment in the IMPACT pancreatic cancer study by the end of Q1 2026, with initial results around year end. A U.S. glioblastoma trial has begun dosing, with plans to enroll ten patients and aim for initial data around the end of 2026, subject to safety review and site expansion.
The company anticipates a regulatory decision in Japan for recurrent head and neck cancer and is progressing its ReSTART pivotal skin cancer trial, expecting to complete enrollment this quarter and finish Modular PMA submission to the FDA toward year end. Alpha Tau continues to ramp manufacturing in Israel and the U.S., build out its New Hampshire facility, invest in automation, and expand intellectual property with dozens of new patent applications and grants while describing its cash burn as stable.
A holder of ordinary shares of issuer DRTS, identified as Raphi Levy, filed a Rule 144 notice to sell 15,000 ordinary shares through Oppenheimer & Co. Inc. on Nasdaq, with an aggregate market value of $106,350.00. The notice states that 70,380,570 ordinary shares were outstanding and that the shares to be sold were originally acquired as 87,500 restricted stock units from the issuer on 08/08/2021.
Over the prior three months, the same seller reported additional sales of ordinary shares: 20,000 shares on 01/08/2026 for gross proceeds of $122,100.00, 10,000 shares on 01/09/2026 for $69,000.00, 10,600 shares on 01/12/2026 for $74,260.00, and 4,400 shares on 01/13/2026 for $31,240.00.